The Global Pulmonary Function Testing Systems Market was valued at USD 3.1 billion in 2025 and is estimated to grow at a CAGR of 6.9% to reach USD 5.9 billion by 2035.
The market is experiencing robust growth due to the rising prevalence of chronic respiratory conditions and supportive government initiatives that promote early diagnosis and management. Pulmonary function testing systems are critical tools for assessing lung performance, measuring airflow, lung volumes, and gas exchange efficiency. Increasing cases of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders, are driving adoption across hospitals, clinics, and home care settings. Innovations, including portable devices, advanced spirometers, and integrated analytical software, are enhancing diagnostic accuracy and patient comfort while promoting widespread acceptance. The industry is also witnessing growing use in occupational health monitoring, industrial applications, and home-based respiratory care. Digital health integration, remote monitoring capabilities, and the rising demand for compact, easy-to-use devices are accelerating the expansion of the pulmonary function testing systems market, particularly in regions emphasizing preventive healthcare and telemedicine solutions.
The handheld segment reached USD 1.8 billion in 2025. These portable devices are favored for their compact design, affordability, and ease of use, making them ideal for point-of-care and home-based monitoring. Handheld pulmonary function testing systems allow healthcare providers and patients to conduct assessments across diverse environments, promoting flexibility and convenience. The devices’ cost-effectiveness enhances their adoption in small clinics, primary care centers, and resource-limited settings. The combination of accessibility, portability, and user-friendly features ensures that the handheld segment maintains its dominance, catering to both clinical and personal health monitoring needs.
The spirometry segment accounted for USD 1.4 billion in 2025 and is expected to grow at a CAGR of 7.2% through 2035. Spirometry remains a cornerstone diagnostic test for assessing lung function and detecting respiratory issues, such as airway obstruction and impaired airflow. Technological advancements, including digital interfaces, wireless connectivity, and integration with health data platforms, have made modern spirometers more precise, intuitive, and portable. These enhancements increase patient compliance and operational efficiency in clinical and home care environments, supporting wider adoption. As the demand for accurate, rapid, and user-friendly pulmonary assessments rises, spirometry systems are anticipated to remain a primary revenue contributor within the market.
U.S. Pulmonary Function Testing Systems Market captured USD 1.4 billion in 2025 and is projected to grow at a CAGR of 5.8% from 2026 to 2035. North America’s leadership in medical technology innovation supports the rapid adoption of advanced pulmonary function testing systems, including digital and portable devices with wireless connectivity. Healthcare providers are increasingly investing in accurate, efficient, and patient-friendly diagnostic tools. Rising healthcare expenditure, coupled with regulatory frameworks emphasizing quality and early detection, further stimulates demand for pulmonary testing solutions. The U.S. market benefits from a combination of advanced infrastructure, high awareness of respiratory health, and increasing prevalence of chronic lung conditions, making it a key driver of global market growth.
Prominent players in the Global Pulmonary Function Testing Systems Market include Baxter, CHEST M.I, COSMED, ECO MEDICS, FUKUDA SANGYO, GANSHORN SCHILLER GROUP, Geratherm Respiratory, Medical Equipment Europe, MGC DIAGNOSTICS, MINATO MEDICAL SCIENCE, MORGAN, ndd Medical Technologies, PHILIPS, Vitalograph, and Vyaire MEDICAL. Key strategies adopted by companies in the Global Pulmonary Function Testing Systems Market focus on innovation, technological integration, and global expansion to strengthen market presence. Businesses are investing in R&D to develop portable, digital, and connected devices that enhance usability, accuracy, and patient engagement. Strategic partnerships, acquisitions, and collaborations are enabling access to new markets, advanced technologies, and manufacturing capabilities. Companies are also emphasizing customized solutions tailored for hospitals, clinics, and home-based monitoring to meet diverse consumer needs. Expanding distribution networks, enhancing customer support, and maintaining compliance with regulatory standards are critical tactics to improve brand trust and penetration. Additionally, firms are leveraging digital platforms to offer remote monitoring, data analytics, and telehealth solutions, ensuring a stronger foothold and competitive advantage in the market.
This product will be delivered within 2-4 business days.
The market is experiencing robust growth due to the rising prevalence of chronic respiratory conditions and supportive government initiatives that promote early diagnosis and management. Pulmonary function testing systems are critical tools for assessing lung performance, measuring airflow, lung volumes, and gas exchange efficiency. Increasing cases of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders, are driving adoption across hospitals, clinics, and home care settings. Innovations, including portable devices, advanced spirometers, and integrated analytical software, are enhancing diagnostic accuracy and patient comfort while promoting widespread acceptance. The industry is also witnessing growing use in occupational health monitoring, industrial applications, and home-based respiratory care. Digital health integration, remote monitoring capabilities, and the rising demand for compact, easy-to-use devices are accelerating the expansion of the pulmonary function testing systems market, particularly in regions emphasizing preventive healthcare and telemedicine solutions.
The handheld segment reached USD 1.8 billion in 2025. These portable devices are favored for their compact design, affordability, and ease of use, making them ideal for point-of-care and home-based monitoring. Handheld pulmonary function testing systems allow healthcare providers and patients to conduct assessments across diverse environments, promoting flexibility and convenience. The devices’ cost-effectiveness enhances their adoption in small clinics, primary care centers, and resource-limited settings. The combination of accessibility, portability, and user-friendly features ensures that the handheld segment maintains its dominance, catering to both clinical and personal health monitoring needs.
The spirometry segment accounted for USD 1.4 billion in 2025 and is expected to grow at a CAGR of 7.2% through 2035. Spirometry remains a cornerstone diagnostic test for assessing lung function and detecting respiratory issues, such as airway obstruction and impaired airflow. Technological advancements, including digital interfaces, wireless connectivity, and integration with health data platforms, have made modern spirometers more precise, intuitive, and portable. These enhancements increase patient compliance and operational efficiency in clinical and home care environments, supporting wider adoption. As the demand for accurate, rapid, and user-friendly pulmonary assessments rises, spirometry systems are anticipated to remain a primary revenue contributor within the market.
U.S. Pulmonary Function Testing Systems Market captured USD 1.4 billion in 2025 and is projected to grow at a CAGR of 5.8% from 2026 to 2035. North America’s leadership in medical technology innovation supports the rapid adoption of advanced pulmonary function testing systems, including digital and portable devices with wireless connectivity. Healthcare providers are increasingly investing in accurate, efficient, and patient-friendly diagnostic tools. Rising healthcare expenditure, coupled with regulatory frameworks emphasizing quality and early detection, further stimulates demand for pulmonary testing solutions. The U.S. market benefits from a combination of advanced infrastructure, high awareness of respiratory health, and increasing prevalence of chronic lung conditions, making it a key driver of global market growth.
Prominent players in the Global Pulmonary Function Testing Systems Market include Baxter, CHEST M.I, COSMED, ECO MEDICS, FUKUDA SANGYO, GANSHORN SCHILLER GROUP, Geratherm Respiratory, Medical Equipment Europe, MGC DIAGNOSTICS, MINATO MEDICAL SCIENCE, MORGAN, ndd Medical Technologies, PHILIPS, Vitalograph, and Vyaire MEDICAL. Key strategies adopted by companies in the Global Pulmonary Function Testing Systems Market focus on innovation, technological integration, and global expansion to strengthen market presence. Businesses are investing in R&D to develop portable, digital, and connected devices that enhance usability, accuracy, and patient engagement. Strategic partnerships, acquisitions, and collaborations are enabling access to new markets, advanced technologies, and manufacturing capabilities. Companies are also emphasizing customized solutions tailored for hospitals, clinics, and home-based monitoring to meet diverse consumer needs. Expanding distribution networks, enhancing customer support, and maintaining compliance with regulatory standards are critical tactics to improve brand trust and penetration. Additionally, firms are leveraging digital platforms to offer remote monitoring, data analytics, and telehealth solutions, ensuring a stronger foothold and competitive advantage in the market.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Test Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Pulmonary Function Testing Systems market report include:- Baxter
- CHEST M.I
- COSMED
- ECO MEDICS
- FUKUDA SANGYO
- GANSHORN SCHILLER GROUP
- Geratherm Respiratory
- medical equipment Europe
- MGC DIAGNOSTICS
- MINATO MEDICAL SCIENCE
- MORGAN
- ndd Medical Technologies
- PHILIPS
- Vitalograph
- Vyaire MEDICAL
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | March 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 3.1 Billion |
| Forecasted Market Value ( USD | $ 5.9 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
